Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production

UK journal publishes complex case of severe pan-drug resistant infection in US liver transplant patient successfully treated with Zaynich

This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins

Sigachi Industries begins disbursing Interim ex-gratia to families of deceased

EMA’s CHMP recommends authorization of Moderna's Covid-19 vaccine Spikevax for SARS-CoV-2 Variant LP.8.1

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision

Concord Biotech successfully completes Russian GMP inspection at its API facility

The inspection was conducted from July 22-25, 2025

48 projects approved under PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs

NATCO Pharma API unit in Mekaguda receives EIR from USFDA

The company received one observation in the Form-483

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population